Merck & Co., Inc.
MRKAPI behind this page
MRK Q1 2026 request
Playground key active
/api/financials?ticker=MRK&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 16,286 | 15,529 | +4.9% |
Show Product Lines breakouts |
|||
| Adempas · Bayer AG | 78 | 68 | +14.7% |
| Adempas · Pharmaceutical | 78 | 68 | +14.7% |
| Adempas · Pharmaceutical | 78 | 68 | +14.7% |
| Alliance revenue - Adempas/Verquvo · Pharmaceutical | 109 | 97 | +12.4% |
| Alliance revenue - Adempas/Verquvo · Pharmaceutical | 109 | 106 | +2.8% |
| Alliance revenue - Koselugo · Pharmaceutical | 161 | 44 | +265.9% |
| Alliance revenue - Lenvima · Pharmaceutical | 176 | 186 | -5.4% |
| Alliance revenue - Lenvima · Pharmaceutical | 80 | 72 | +11.1% |
| Alliance revenue - Lenvima · Pharmaceutical | 256 | 258 | -0.8% |
| Alliance revenue - Lynparza · Pharmaceutical | 149 | 145 | +2.8% |
| Alliance revenue - Lynparza · Pharmaceutical | 192 | 168 | +14.3% |
| Alliance revenue - Lynparza · Pharmaceutical | 341 | 312 | +9.3% |
| Alliance Revenue - Reblozyl · Pharmaceutical | 128 | 101 | +26.7% |
| Alliance Revenue - Reblozyl · Pharmaceutical | 20 | 18 | +11.1% |
| Alliance Revenue - Reblozyl · Pharmaceutical | 148 | 119 | +24.4% |
| Bridion · Pharmaceutical | 427 | 378 | +13.0% |
| Bridion · Pharmaceutical | 45 | 63 | -28.6% |
| Bridion · Pharmaceutical | 472 | 441 | +7.0% |
| Capvaxive · Pharmaceutical | 118 | 106 | +11.3% |
| Capvaxive · Pharmaceutical | 23 | 1 | +2200.0% |
| Capvaxive · Pharmaceutical | 142 | 107 | +32.7% |
| Companion Animal · Animal Health | 308 | 308 | 0.0% |
| Companion Animal · Animal Health | 419 | 356 | +17.7% |
| Companion Animal · Animal Health | 727 | 664 | +9.5% |
| Delstrigo · Pharmaceutical | 10 | 15 | -33.3% |
| Delstrigo · Pharmaceutical | 65 | 52 | +25.0% |
| Delstrigo · Pharmaceutical | 75 | 67 | +11.9% |
| Dificid · Pharmaceutical | 24 | 72 | -66.7% |
| Dificid · Pharmaceutical | 10 | 11 | -9.1% |
| Dificid · Pharmaceutical | 34 | 83 | -59.0% |
| Gardasil/Gardasil 9 · Pharmaceutical | 485 | 536 | -9.5% |
| Gardasil/Gardasil 9 · Pharmaceutical | 585 | 790 | -25.9% |
| Gardasil/Gardasil 9 · Pharmaceutical | 1,069 | 1,327 | -19.4% |
| Isentress/Isentress HD · Pharmaceutical | 35 | 51 | -31.4% |
| Isentress/Isentress HD · Pharmaceutical | 24 | 39 | -38.5% |
| Isentress/Isentress HD · Pharmaceutical | 59 | 90 | -34.4% |
| Janumet · Pharmaceutical | 68 | 65 | +4.6% |
| Janumet · Pharmaceutical | 139 | 182 | -23.6% |
| Janumet · Pharmaceutical | 207 | 247 | -16.2% |
| Januvia · Pharmaceutical | 252 | 344 | -26.7% |
| Januvia · Pharmaceutical | 116 | 204 | -43.1% |
| Januvia · Pharmaceutical | 367 | 549 | -33.2% |
| Keytruda Qlex · Pharmaceutical | 106 | — | — |
| Keytruda Qlex · Pharmaceutical | 21 | — | — |
| Keytruda Qlex · Pharmaceutical | 128 | — | — |
| Keytruda · Pharmaceutical | 4,599 | 4,308 | +6.8% |
| Keytruda · Pharmaceutical | 3,307 | 2,897 | +14.2% |
| Keytruda · Pharmaceutical | 7,906 | 7,205 | +9.7% |
| Lagevrio · Pharmaceutical | 16 | 35 | -54.3% |
| Lagevrio · Pharmaceutical | 12 | 67 | -82.1% |
| Lagevrio · Pharmaceutical | 28 | 102 | -72.5% |
| Lagevrio · Ridgeback Biotherapeutics LP | 28 | 102 | -72.5% |
| Livestock · Animal Health | 211 | 194 | +8.8% |
| Livestock · Animal Health | 853 | 730 | +16.8% |
| Livestock · Animal Health | 1,064 | 924 | +15.2% |
| Ohtuvayre · Pharmaceutical | 131 | — | — |
| Ohtuvayre · Pharmaceutical | 131 | — | — |
| Other pharmaceutical · Pharmaceutical | 166 | 227 | -26.9% |
| Other pharmaceutical · Pharmaceutical | 608 | 637 | -4.6% |
| Other pharmaceutical · Pharmaceutical | 775 | 865 | -10.4% |
| Prevymis · Pharmaceutical | 135 | 102 | +32.4% |
| Prevymis · Pharmaceutical | 138 | 106 | +30.2% |
| Prevymis · Pharmaceutical | 272 | 208 | +30.8% |
| ProQuad/M-M-R II/Varivax · Pharmaceutical | 409 | 423 | -3.3% |
| ProQuad/M-M-R II/Varivax · Pharmaceutical | 129 | 116 | +11.2% |
| ProQuad/M-M-R II/Varivax · Pharmaceutical | 538 | 539 | -0.2% |
| RotaTeq · Pharmaceutical | 165 | 164 | +0.6% |
| RotaTeq · Pharmaceutical | 42 | 64 | -34.4% |
| RotaTeq · Pharmaceutical | 206 | 228 | -9.6% |
| Vaxneuvance · Pharmaceutical | 123 | 139 | -11.5% |
| Vaxneuvance · Pharmaceutical | 78 | 92 | -15.2% |
| Vaxneuvance · Pharmaceutical | 202 | 230 | -12.2% |
| Verquvo · Bayer AG | 9 | 9 | 0.0% |
| Welireg · Pharmaceutical | 152 | 123 | +23.6% |
| Welireg · Pharmaceutical | 47 | 15 | +213.3% |
| Welireg · Pharmaceutical | 199 | 137 | +45.3% |
| Winrevair · Pharmaceutical | 477 | 268 | +78.0% |
| Winrevair · Pharmaceutical | 48 | 12 | +300.0% |
| Winrevair · Pharmaceutical | 525 | 280 | +87.5% |
| Zerbaxa · Pharmaceutical | 52 | 42 | +23.8% |
| Zerbaxa · Pharmaceutical | 30 | 28 | +7.1% |
| Zerbaxa · Pharmaceutical | 82 | 70 | +17.1% |
Show Business Segments breakouts |
|||
| Animal Health · Non Us | 1,272 | 1,086 | +17.1% |
| Animal Health · Operating Segments | 1,791 | 1,588 | +12.8% |
| Animal Health · US | 519 | 502 | +3.4% |
| Pharmaceutical · Non Us | 5,837 | 5,711 | +2.2% |
| Pharmaceutical · Operating Segments | 14,349 | 13,638 | +5.2% |
| Pharmaceutical · US | 8,512 | 7,927 | +7.4% |
Show Geography breakouts |
|||
| Asia Pacific | 738 | 689 | +7.1% |
| CN | 390 | 702 | -44.4% |
| EMEA | 3,886 | 3,454 | +12.5% |
| JP | 555 | 669 | -17.0% |
| Latin America | 874 | 792 | +10.4% |
| Non Us | 7,122 | 7,007 | +1.6% |
| Non Us · Corporate Non Segment | 13 | 210 | -93.8% |
| Non Us · Operating Segments | 7,109 | 6,797 | +4.6% |
| Other | 679 | 701 | -3.1% |
| US | 9,164 | 8,522 | +7.5% |
| US · Corporate Non Segment | 133 | 93 | +43.0% |
| US · Operating Segments | 9,031 | 8,429 | +7.1% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Foreign Exchange Contract | -98 | 74 | -232.4% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 146 | 303 | -51.8% |
| Operating Segments | 16,140 | 15,226 | +6.0% |
Show Counterparty Name breakouts |
|||
| Bayer AG · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 196 | 183 | +7.1% |
| Cost of Revenue | 4,195 | 3,419 | +22.7% |
Show Business Segments breakouts |
|||
| Animal Health · Operating Segments | 675 | 600 | +12.5% |
| Pharmaceutical · Operating Segments | 1,553 | 1,573 | -1.3% |
Show Counterparty Name breakouts |
|||
| AstraZeneca · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 84 | 83 | +1.2% |
| Bayer AG · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 67 | 58 | +15.5% |
| Eisai · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 13 | 60 | -78.3% |
| Ridgeback Biotherapeutics LP · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 54 | 53 | +1.9% |
| Research & Development | 12,592 | 3,621 | +247.7% |
Show Business Segments breakouts |
|||
| Animal Health · Operating Segments | 112 | 95 | +17.9% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 12,404 | 3,477 | +256.7% |
Show Counterparty Name breakouts |
|||
| AstraZeneca · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 5 | 12 | -58.3% |
| Bayer AG · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 17 | 24 | -29.2% |
| Daiichi Sankyo · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 160 | 128 | +25.0% |
| Eisai · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 2 | 5 | -60.0% |
| Moderna, Inc. · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 90 | 86 | +4.7% |
| Selling, General & Administrative | 2,700 | 2,552 | +5.8% |
Show Business Segments breakouts |
|||
| Animal Health · Operating Segments | 282 | 260 | +8.5% |
| Pharmaceutical · Operating Segments | 1,332 | 1,402 | -5.0% |
Show Counterparty Name breakouts |
|||
| AstraZeneca · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 24 | 32 | -25.0% |
| Bayer AG · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 12 | 29 | -58.6% |
| Daiichi Sankyo · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 12 | 9 | +33.3% |
| Eisai · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 27 | 31 | -12.9% |
| Moderna, Inc. · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 8 | 6 | +33.3% |
| Ridgeback Biotherapeutics LP · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 11 | 13 | -15.4% |
| Interest Expense | 479 | 313 | +53.0% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 479 | 313 | +53.0% |
| Interest Income | 35 | 109 | -67.9% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 35 | 109 | -67.9% |
| Other Non-Operating Income (Expense) | 138 | -35 | +494.3% |
Show Business Segments breakouts |
|||
| Pharmaceutical · Operating Segments | 55 | 49 | +12.2% |
| Income Before Taxes | -3,534 | 5,903 | -159.9% |
Show Business Segments breakouts |
|||
| Animal Health · Operating Segments | 722 | 634 | +13.9% |
| Pharmaceutical · Operating Segments | 11,519 | 10,712 | +7.5% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 106 | 202 | -47.5% |
| Operating Segments | 12,241 | 11,346 | +7.9% |
| Income Tax Expense (Benefit) | 709 | 818 | -13.3% |
| Net Income | -4,243 | 5,085 | -183.4% |
| Net Income | -4,240 | 5,079 | -183.5% |
Show Equity Components breakouts |
|||
| Retained Earnings | -4,240 | 5,079 | -183.5% |
| Comprehensive Income | -4,013 | 5,059 | -179.3% |
| Other Comprehensive Income | 227 | -20 | +1235.0% |
| EPS (Basic) | -1.72 | 2.01 | -185.6% |
| EPS (Diluted) | -1.72 | 2.01 | -185.6% |
| Wtd Avg Shares (Basic) | 2,472 | 2,523 | -2.0% |
| Wtd Avg Shares (Diluted) | 2,472 | 2,531 | -2.3% |
| Net Income Loss Attributable To Noncontrolling Interest | -3 | 6 | -150.0% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | -3 | 6 | -150.0% |
| Net Income Loss Available To Common Stockholders Basic | -4,240 | 5,079 | -183.5% |
| Foreign Currency Transaction Gain Loss Before Tax | 38 | 90 | -57.8% |
| Income Loss From Equity Method Investments (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Pharmaceutical · Operating Segments | 62 | 58 | +6.9% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 62 | 58 | +6.9% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 5,327 | 8,629 | -38.3% |
| Marketable Securities (Current) | 375 | 599 | -37.4% |
| Accounts Receivable | 12,210 | 10,790 | +13.2% |
| Inventory | 6,479 | 6,196 | +4.6% |
| Total Current Assets | 35,015 | 35,503 | -1.4% |
Show Counterparty Name breakouts |
|||
| AstraZeneca · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 401 | 358 | +12.0% |
| Bayer AG · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 162 | 160 | +1.2% |
| Eisai · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 252 | 263 | -4.2% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 25,433 | — | — |
Show Geography breakouts |
|||
| Asia Pacific | 842 | — | — |
| CN | 213 | — | — |
| EMEA | 8,966 | — | — |
| JP | 136 | — | — |
| Latin America | 128 | — | — |
| Other | 51 | — | — |
| US | 15,097 | — | — |
| Goodwill | 21,581 | 21,684 | -0.5% |
| Intangible Assets (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Adempas · Licenses and Other | 239 | 353 | -32.3% |
| Alliance revenue - Lenvima · Licenses and Other | 188 | 382 | -50.8% |
| Koselugo · Licenses and Other | 36 | 48 | -25.0% |
| Lynparza · Licenses and Other | 762 | 1.1 | +69172.7% |
| Verquvo · Licenses and Other | 37 | 42 | -11.9% |
| Other Non-Current Assets | 19,806 | — | — |
| Marketable Securities (Non-Current) | 1,105 | 616 | +79.4% |
| Total Assets | 128,685 | 115,122 | +11.8% |
| Current Liabilities | |||
| Accounts Payable | 3,863 | 3,784 | +2.1% |
| Total Current Liabilities | 26,945 | 25,174 | +7.0% |
| Debt Current | 2,444 | 1,360 | +79.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 46,673 | 33,484 | +39.4% |
| Deferred Tax Liabilities | 1,494 | 1,409 | +6.0% |
| Other Non-Current Liabilities | 7,642 | 6,655 | +14.8% |
| Stockholders' Equity | |||
| Common Stock | 1,788 | 1,788 | 0.0% |
| Retained Earnings | 66,721 | 66,097 | +0.9% |
| Accumulated Other Comprehensive Income | -4,060 | -4,965 | +18.2% |
| Total Stockholders' Equity | 45,878 | 48,335 | -5.1% |
| Total Liabilities & Equity | 128,685 | 115,122 | +11.8% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 185 | 195 | -5.1% |
| Deferred Income Taxes | -315 | -186 | -69.4% |
| Other Non-Cash Items | 20 | 109 | -81.7% |
| Net Cash from Operations | 3,918 | 2,500 | +56.7% |
| Investing Activities | |||
| Capital Expenditures | -991 | -1,328 | +25.4% |
| Other Investing Activities | -66 | -20 | -230.0% |
| Net Cash from Investing | -10,210 | -1,487 | -586.6% |
| Financing Activities | |||
| Share Repurchases | -874 | -1,164 | +24.9% |
| Net Cash from Financing | -2,981 | -5,755 | +48.2% |
| Supplemental | |||
| Interest Paid | 342 | 233 | +46.8% |
| Other Cash Flow | |||
| Net Change in Cash | -9,292 | -4,586 | -102.6% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.